Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesCytogenetic StudiesCPT cpt-88239-solid-tumor-cell-culture-neoplastic-disorder
    Ask Trek AI about this page

    CPT 88239: Cell Culture From Solid Tumor for Neoplastic Disorder

    CPT code 88239 describes a laboratory procedure in which a lab analyst cultures cells derived from a solid tumor to grow a cell culture for evaluation of a neoplastic disorder; the service is cell culture preparation typically performed in a clinical cytology or pathology laboratory setting (inpatient or outpatient hospital laboratory or independent reference lab) to support downstream diagnostic or ancillary testing.

    For related coverage guidance, see recent payer policy updates: Oral Cancer Screening and Testing, RTM Testing for Alpha-1 Antitrypsin Deficiency, Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policy.

    Customize your policy alerts

    Sign up for cpt 88239 policy alerts

    Get alerted when payer policies referencing 88239 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 62-year-old patient with a newly diagnosed solid neoplasm (e.g., lung, breast, or colorectal carcinoma) undergoes a diagnostic tumor biopsy. The surgical pathology team receives the resection or core biopsy specimen and forwards a portion for specialized laboratory culture to establish a viable cell culture from the solid tumor for downstream testing (cytogenetics, drug sensitivity assays, molecular studies, or creation of patient-derived xenograft material). The clinical workflow: biopsy or surgical specimen collection in an ambulatory surgical center or inpatient operating room → transport to pathology/clinical laboratory with appropriate specimen labeling and requisition → accessioning and grossing by pathology → selection and aseptic processing of viable tumor tissue by the laboratory analyst → placement into culture media and incubation under defined conditions documented in the laboratory information system → monitoring and expansion of tumor cell colonies for subsequent analyses. Typical site of service: hospital pathology laboratory, hospital-based outpatient laboratory, or specialized cancer center laboratory. Typical patient scenario: specimen obtained during biopsy or surgical excision for a solid tumor; physician orders culture for diagnostic cytogenetics, research, or therapeutic planning.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    88309Surgical pathology, gross and microscopic examination of tissue, level IVPerformed on the same specimen to provide diagnostic pathology that guides whether culture is indicated.
    88384Special stains, immunohistochemistry (IHC) qualitative; each antibody stainUsed on tissue sections to subtype tumors prior to or in parallel with culture-based testing.
    88104Cytopathology, smears, initial interpretationMay be performed on needle biopsy specimens before or instead of culture to provide rapid diagnosis.
    88237Cytogenetic analysis; cell culture for chromosome studies, initiation of cell cultureRelated cytogenetic cell culture work that may be ordered alongside tumor cell culture for chromosomal analysis.
    89240Development of primary cell cultureLaboratory code for propagation of cells; used in workflows that require expansion of tumor cells for testing.

    Related Modifiers

    9 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    207L00000X
    207K00000X
    363A00000X
    207X00000X
    292200000X
    133VN1005X
    103TC0700X

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Carrier Testing Panels for Genetic Diseases (for Kentucky Only)UnitedHealthcare2026-10-01
    Genetic Testing for Neurological Disorders (for Kansas Only)UnitedHealthcare2026-10-01
    Genetic and Molecular TestingProvidence Health Plan2026-10-01
    Cell-Free Fetal DNA Testing (for Idaho Only)UnitedHealthcare2026-10-01
    Next Generation Sequencing for Minimal Residual Disease DetectionProvidence Health Plan2026-10-01
    Pharmacogenetic Panel Testing (for Kansas Only)UnitedHealthcare2026-10-01
    Non-Covered Genetic Panel TestsProvidence Health Plan2026-10-01

    Related Codes

    CPT-88230-LYMPHOCYTE-TISSUE-CULTURE-NONNEOPLASTIC-DISORDER

    CPT 88230: Lymphocyte Culture for Nonneoplastic Disorder

    CPT-88233-TISSUE-CULTURE-SKIN-SOLID-TISSUE-NONNEOPLASTIC

    CPT 88233: Tissue Culture for Nonneoplastic Disorders

    CPT-88235-AMNIOTIC-FLUID-CHORIONIC-VILLUS-TISSUE-CULTURE

    CPT 88235: Tissue Culture Preparation from Amniotic Fluid or Chorionic Villi

    CPT-88237-BONE-MARROW-BLOOD-CELL-CULTURE-NEOPLASTIC-DISORDER

    CPT 88237: Cell Culture for Neoplastic Disorders

    CPT-88240-CELL-LINE-CRYOPRESERVATION-STORAGE

    CPT 88240: Cryopreservation and Storage of Cell Line

    CPT-88241-THAW-AND-EXPAND-FROZEN-CELLS-SINGLE-ALIQUOT

    CPT 88241: Thaw and Expand Previously Frozen Cells, Single Aliquot

    CPT-88245-CHROMOSOME-ANALYSIS-SISTER-CHROMATID-EXCHANGE-SCE

    CPT 88245: Chromosome Analysis for Sister Chromatid Exchange

    CPT-88248-CHROMOSOME-ANALYSIS-BREAKAGE-SYNDROME

    CPT 88248: Chromosome Analysis for Breakage Syndromes

    CPT-88249-CHROMOSOME-ANALYSIS-BREAKAGE-SYNDROME-CLASTOGEN-STRESS

    CPT 88249: Chromosome Analysis for Breakage Syndrome, 100-Cell Clastogen Test

    CPT-88261-CHROMOSOME-ANALYSIS-KARYOTYPE-BANDING

    CPT 88261: Chromosome Analysis, Karyotype with Banding

    Showing 1–10 of 26

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.